• The role of Vitex agnus castus in gynecological endocrinology

The role of Vitex agnus castus in gynecological endocrinology

HEALTH OF WOMAN. 2016.10(116):24–27
 

The role of Vitex agnus castus in gynecological endocrinology
 

Wuttke W., Zaidlova-Wuttke D., Jarry H., Artymuk N.

Department of endocrinology, University of gцttingen, Germany

SBEI HPE Kemerovo state medical Academy health Ministry of the Russian Federation

Published: GYNECOLOGY. V. 14; No. 1.


Extracts of the driedfruits of chasteberry (Vitex agnus castus – VAC) contain dopaminergic compounds which are inhibitory to pituitary prolactin release. The development of premenstrual mastalgia as well as of fibrocystic mastopathy involves an action of prolactin. Hence, treatment with VAC is helpful to prevent these mammary gland symptoms. Prolactin is also involved in thefunction of the corpus luteum and patients with a latent hyperprolactinemia often sufferfrom a corpus luteum insufficiency where treatment with VAC extracts may also be helpful to improve fertility.


Key words: chasteberry, Vitex agnus castus, mastodynia, premenstrual symptom, corpus luteum insufficiency, prolactin, dopamine.


REFERENCES

1. Wuttke W, Gorkow С, Seidlova-Wuttke D. 2006. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 13:185–96. https://doi.org/10.1097/01.gme.0000174470.44822.57; PMid:16645532

2. Wuttke W, Jarry H, Christoffel V et al. 2003. Chaste tree (Vitex agnus-castus) – pharmacology and clinical indications. Phytomedicine 10:348–57. https://doi.org/10.1078/094471103322004866ж PMid:12809367

3. Gorkow C, Wuttke W. 1999. Evidence of efficacy of Vitex agnus castus preparations. Phytopharmaka:189–208.

4. Halaska M, Raus К, Bкles P et al. 1998. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol 63:388–92.

5. Wuttke W, Splitt G, Gorkow С et al. 1997. Behandlung zyklusabhдngiger Brustschmerzen mit einem Agnus ca-stus-haltigen Arzneimittel-Ergebnisse einer rando-misierten, plazebokontrollierten Doppelblindstudie. Geburtsh и Frauenheilk 57:569–74. https://doi.org/10.1055/s-2007-1023139

6. Kubist a E, Muller G, Sponaf. 1987. Treatment of mastopathies with cyclic mastodynia. Clinical results and hormonal profiles.RevFr Gynecol Obstet 82:221–7.

7. Kumar S, Mansel RE, Hughes LE et al. 1985. Prediction of response to endocrine therapy in pronounced cyclical mastalgia using dynamic tests of prolactin release. Clin Endocrinol (Oxf) 23:699–704. https://doi.org/10.1111/j.1365-2265.1985.tb01131.x

8. Suginami H, Ito T, Hamada К et al. 1986. Serum prolactin levels during sleep and in metoclopramide stimulation in normoprolactinemic anovulation and ovulation induction with bromocriptine. Nippon Sanka Fujinka Gakkai Zasshi 38:728–34.

9. Wuttke W, Pitzel L, Seidlova-Wuttke D et al. 2001. LH pulses and the corpus luteum: the luteal phase deficiency LPD. Vitam Horm 63:131–58. https://doi.org/10.1016/S0083-6729(01)63005-X

10. Freeman ME, Kanyicska B, Lerant A et al. 2000. Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–631.

11. Dogliotti L, Mansel RE. 1989. Bromocriptine treatment of cyclical mastalgia/fibrocystic breast disease: update on the European trial. Br J Clin Pract Suppl 68:26-32; dis. 49–53.

12. Nazli K, Syed S, Mahmood MR et al. 1989. Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J Clin Pract 43:322–7.

13. Schwibbe M BD, Wuttke W, Calne et al. 1983. EEG and psycho-logical effects oflisuride in women with premenstrueal tension. Lisurides and Other Dopmanine Agonists.

14. Milewicz A, Gejdel E, Sworen H et al. 1993. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 43:752–6.

15. Wuttke WGC, Jarry H. 1995. Dopaminergic compounds in Vitex agnus castus. Phyto-Pharmaka-Forschung und klinische Anwendung.:81–91.

16. Jarry H, Leonhardt S, Gorkow С et al. 1994. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 102:448–54. https://doi.org/10.1055/s-0029-1211317; PMid:7890021

17. Ono M, Nagasawa Y, Iked T et al. 2009. Three new diterpenoidsfrom the fruit of Vitex agnus castus. Chem Pharm Bull (Tokyo) 57:1132–5. https://doi.org/10.1248/cpb.57.1132

18. Christoffel V, Spengler B, Jarry H et al. 1999. Prolactin inhibiting dopaminergic activity of diterpenes from Vitex agnus castus Phytopharmaka:209–14.

19. Artymuk NV. 2010. Vitex agnus castus extract administered for luteal-phase defect treatment. GReproduktionsmedт Endokrinol 7:362.

20. Gerhard, Patek A, Monga В et al. 1998. MastodynonR bei weiblicher Sterilitдt. Forsch Komplementarmed 5:272–8. https://doi.org/10.1159/000021154; PMid:9973660

21. Schellenberg R. 2001. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 322:134–7. https://doi.org/10.1136/bmj.322.7279.134; PMid:11159568 PMCid:PMC26589

22. Prilepskaya VN. 2006. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 55S: 55–63.

23. Atmaca M, Kumru S, Tezcan E. 2003. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 18:191–5. https://doi.org/10.1002/hup.470; PMid:12672170

24. Bogorad RL, Courtillot C, Mestayer С et al. 2008. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sсі USA 105:14533–8. https://doi.org/10.1073/pnas.0800685105; PMid:18779591 PMCid:PMC2567233

25. Courtillot C, Chakhtoura Z, Bogorad R et al. 1995. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breastfibroadenomas. G Clin Endocrinol Metab.:271-9.

26. Daniele С, Thompson Coon J, Pittler MH et al. 2005. Vitex agnus castus: a systematic review of adverse events. DrugSaf 28:319-32. https://doi.org/10.2165/00002018-200528040-00004